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Summary We have examined by immunohistochemistry the ability of breast carcinomas to produce pep-
sinogen C, an aspartyl proteinase usually involved in the digestion of proteins in the stomach. A total of 113
out of 245 breast tumours (46%) were positive for pepsinogen C immunostaining. There was a significant
association between pepsinogen C and oestrogen receptors with proteinase levels higher (HSCORE) in
oestrogen receptor positive tumours than in oestrogen receptor negative. There was also a significant
association between pepsinogen C and histological grade, pepsinogen C levels being higher in well and
moderately differentiated breast carcinomas than in poorly differentiated tumours. On the basis of these
results, we suggest that pepsinogen C may be useful as a marker of good prognosis in breast cancer.
Breast tumour cells are known to overproduce or to induce
stromal cells to elaborate a variety of proteolytic enzymes
including metalloproteinases like collagenases and
stromelysins (Monteagudo et al., 1990; Basset et al., 1990),
aspartyl-proteinases such as cathepsin D (Rochefort et al.,
1987; S'anchez et al., 1993), serine-proteinases like plas-
minogen activators (Sappino et al., 1987) or cysteine pro-
teinases such as cathepsins B and L (Sloane et al., 1981;
Chauhan et al., 1991). All of them are secreted as precursors
of higher molecular weight that, after activation, may cont-
ribute to degrade the extracellular matrix, thereby facilitating
tumour growth, invasion and metastasis (Liotta, 1988). A
series of clinical studies has provided additional support to
this proposed role for proteinases in breast cancer. Thus, and
although data are not univocal (Duffy et al., 1988; Henry et
al., 1990), the increased expression of proteolytic enzymes in
breast carcinomas has been usually correlated with a poor
clinical outcome of the disease (Spyratos et al., 1989; Tandon
et al., 1990; Duffy et al., 1990).
As part of our studies directed to investigate the involve-
ment of proteolytic enzymes in breast cancer, we have
recently described that some breast carcinomas and mam-
mary epithelium surrounding breast cysts produce an
aspartyl-proteinase closely related to gastric pepsinogen C
(Sa'nchez et al., 1992a). The finding of this new proteinase
produced by pathological breast tissue prompted us to
evaluate its potential interest as a tumour marker. In this
work, we have studied its expression in a series of 245 breast
tumours by using immunohistochemical staining. In addition,
we have examined the possible correlation of these results on
pepsinogen C expression with the most common prognostic
parameters in breast cancer.
Antiserum against the purified protein was raised in rabbits
as described by Vaitukaitis (1981), and its specificity
confirmed by immunoblot analysis as previously described
(Sanchez et al., 1992b).
Immunohistochemical assays were performed on 6gAm
formalin-fixed paraffin-embedded tissue sections using the
avidin-biotin method (Hsu et al., 1981). Slides were scored
according to the procedure described by McCarty et al.
(1986), which incorporates both the intensity (I) and the
percentage of cells staining at each intensity (PC). Intensities
were classified from 0 (no staining) to 3 (very strong stain-
ing). For each tissue section, a value designated HSCORE
(McCarty et al., 1986) was obtained by applying the follow-
ing algorithm: HSCORE = E((I + 1) x PC). Statistical
analysis of data was performed using Student's t-test or
ANOVA-test followed by the post-ANOVA Newman-Keuls
test.
Results
Table I shows the clinical characteristics of the 245 patients
included in this study. Pepsinogen C expression in the corres-
Table I Characteristics of patients and tumours
Patients
Tumours Materials and methods
This study was performed on a group of 245 women who
had undergone surgery for primary breast carcinoma at Hos-
pital de Jove (Asturias, Spain) from 1987 to 1992. The
patients' characteristics with respect to age, menopausal
status and clinical staging of the disease are shown in Table
I. Tumours were graded histologically according to the
criteria of Bloom and Richardson (1957). Nodal status was
assessed histopathologically.
Pepsinogen C was purified from human stomach as previ-
ously described (Foltmann & Jensen 1982), and its identity
confirmed by N-terminal amino acid sequence analysis.
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Total
Age
Mean
Range
Menopausal status
Premenopausal
Postmenopausal
Size
T1 (<2 cm)
T2 (2-5 cm)
Ti (>5 cm)
Nodal status
No
N+
Metastasis at time of diagnosis
Mo
Ml
Histological grade
I
II
III
Oestrogen receptor
Positive
Negative
245
59
26-90
75
170
61
114
70
116
129
236
9
92
125
28
68
49
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Figure 1 Immunoblot analysis of proteins from gastric mucosa
and breast cyst fluid. Aliquots of radioactive molecular weight
markers or samples were fractionated by SDS-PAGE, transferred
to nitrocellulose sheets, incubated with antibodies against gastric
pepsinogen C and developed with radioactive protein A.
c
ponding breast tissue sections was evaluated by immunos-
taining using antibodies raised against the purified pro-
teinase. The antiserum specificity was assessed by Western-
blot analysis of gastric mucosa and breast cyst fluid (Figure
1). Semiquantitative analysis of the stained tissues revealed a
wide variability in both the percentage and intensity of
tumour cells stained with the pepsinogen C antiserum. A
total of 113 tumours (46%) were positive with an average
HSCORE value of 76.9. Representative examples of positive
and negatively stained breast tumours and a positive control
of normal human stomach are shown in Figure 2.
To determine the possible relationship between pepsinogen
C expression and disease status, women included in the study
Table II Pepsinogen C HSCORE in tumour tissues classified
according to different characteristics
Patient and tumour HSCORE
characteristics No. Mean ± s.e.m. Range
Menopausal status
Premenopausal 75 60.3 ± 9.9 0-340
Postmenopausal 170 84.3 ± 7.5 0-340
Tumour size
T, (<2cm) 61 79.3± 12.4 0-340
T2 (2-5cm) 114 72.6± 8.9 0-340
Ti (>5 cm) 70 81.9± 11.3 0-300
Nodal status
No 116 79.6± 8.6 0-300
N+ 129 73.4 8.6 0-340
Histological grade
I 92 86.9 10.6a 0-340
II 125 80.8 8.4a 0-340
III 28 26.8 10.1 0-160
Oestrogen receptor
Positive 68 90.5 ± 12.4b 0-300
Negative 49 47.3 ± 11.6 0-300
ap <0.05 vs histological grade III. bp <0.05 vs oestrogen receptor
negative.
.EI
d
Figure 2 Immunohistochemical staining of pepsinogen C in human breast cancer. Positive tumours a,b, negative tumour c and
gastric mucosa d. Tissues sections were immunostained with anti-gastric pepsinogen C (1:600 dilution). Sections were
counterstained with formaldehyde-thionine (Tolivia & Tolivia, 1985). Original magnification a,c,d 160 X; (b) 250 x.PEPSINOGEN C IN BREAST CANCER 639
were classified into different groups according to several
clinopathological parameters and the presence of the pro-
teinase was evaluated in each group. Table II shows the
distribution of pepsinogen C in relation to tumour size. The
highest mean HSCORE value was found in large tumours
(T3/4: 81.9 vs TI: 79.3 or T2: 72.6). However, these differences
were not statistically significant. Similar results were obtained
when the possible relationships between pepsinogen C
immunostaining and axillary nodal involvement or
menopausal status were examined. As shown in Table II, the
average pepsinogen C values were slightly higher in node-
negative women than in node-positive patients (79.6 vs 73.4)
or in tumours of postmenopausal women than in those from
premenopausal women (84.3 vs 60.3), but these differences
were not significant. Finally, we compared the HSCORE
pepsinogen C values in breast tumours from different his-
tological grade. As shown in Table II, the proteinase was
expressed at lower levels in poorly differentiated tumours
(grade III: 26.8) than in those moderately (grade IA: 80.8) or
well differentiated (grade I: 86.9). Statistical analysis of these
data revealed that the observed differences were significant at
the P<0.05 level.
To investigate the possible relationship between pepsinogen
C expression and oestrogen receptor status in breast
tumours, we compared the HSCORE pepsinogen C values
with the tumour cytosolic concentration of this biochemical
parameter measured by enzyme immunoassay. As shown in
Table II, the average concentration of the proteinase was
higher in ER+ tumours (>10 fmol mg-1) than in those
ER- (90.5 vs 47.3). Statistical analysis revealed that these
differences were significant (P<0.05).
Discussion
Our preliminary finding indicating that some breast tumours
produce pepsinogen C (Sa'nchez et al., 1992a), a gastric pro-
teinase mainly involved in the digestion of proteins in the
stomach (Samloff, 1989), prompted us to study the expres-
sion of this enzyme in a large series of breast carcinomas.
The results obtained have provided evidence that more than
40% of these tumours present immunohistochemically detec-
table pepsinogen C. In addition, a considerable variation in
both the proportion of tumour cells expressing the proteinase
and the intensity of staining was observed. This wide
variability may reflect the existence of breast tumours
differing in clinical behaviour, which could be of importance
in relation to the possible value of pepsinogen C as a new
prognostic marker in breast cancer.
As a first step to examine this question, and considering
the short follow-up of patients whose tumour pepsinogen C
values have been determined in the present work, we tried to
find correlations of this zymogen with common prognostic
factors in breast carcinoma. These analyses revealed the
absence of a significant relationship between pepsinogen C
expression and several patient and tumour characteristics
such as axillary node status, menopausal status and tumour
size. By contrast, expression levels of the proteinase were
significantly associated with the histological grade of tumours
and oestrogen receptor status. Thus, higher levels of pep-
sinogen C were found in well and moderately differentiated
tumours than in those poorly differentiated. Similarly, pep-
sinogen C values were higher in oestrogen receptor positive
tumours. Considering that both conditions confer a prognos-
tic advantage to breast cancer patients, it is tempting to
speculate that pepsinogen C expression may be a marker of
good prognosis in breast cancer.
The finding of proteolytic enzymes indicative of lesions
with favorable evolution is not unprecedented. Thus, tissue-
type plasminogen activator (t-PA) is associated to breast
tumours that present a favourable prognosis (Duffy et al.,
1988). In addition, and although most authors have proposed
that cathepsin D is a marker of poor clinical outcome of the
disease, Henry et al. (1990) have suggested that this
oestrogen-induced proteinase is a marker of good prognosis
in breast cancer. Since cathepsin D is a widely distributed
enzyme, these discrepancies have been attributed to the low
specificity of biochemical assays based on tumour extracts
containing a variable number of non-tumour cathepsin D
producing cells, although other explanations like different
properties of antibodies used or variations in the follow-up
period cannot be ruled out (Isola et al., 1993; Winstanley et
al., 1993). In this regard, the finding that pepsinogen C is not
produced by normal resting mammary gland together with its
highly restricted expression in human tissues (Samloff, 1989),
may be of importance in relation to its value as a tumour
marker in breast cancer since it could offer advantages over
those widely expressed biochemical markers. The long-term
clinical follow-up of women whose tumours have been
analysed in this work, will be useful to define the biological
significance of the expression of this gastric zymogen by
breast tumour cells and its prognostic significance in breast
cancer.
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